Dr. Arukha earned his Master in Biotechnology degree from the Department of Biotechnology (DBT), India, at the Visva Bharati Central University and went on to pursue his Ph. D. there. During his doctoral studies he worked on a novel bacterium which constitutively produced β-galactosidase enzyme, and characterized the promoter responsible for the trait. He simultaneously worked on a novel xylanase-producing thermophilic bacterium and characterized the thermostable and alkaline stable xylanase. From 2013-2015, he researched in the field of Reproductive Immunology as a Postdoctoral Associate at the National Institute of Immunology, New Delhi, India wherein he worked on a DBT sponsored project on developing immuno-contraceptive vaccine using various recombinant fusion proteins. That novel construct is currently being tested on dogs. Simultaneously, he worked on Plasmodium falciparum Msp19 protein which is presently being commercialized at the Oscar Medicare Pvt. Ltd. where Dr. Arukha worked in the capacity of a Scientist. He served as an Assistant professor of Clinical Microbiology at the Asian Institute of Public Health, India before coming to Gainesville, Florida. He worked as a Postdoctoral Associate with Prof. Roy Curtiss III from September 2016 to July 2019 on developing immunocontraceptive vaccine using Recombinant Attenuated Salmonella Vaccine (RASV) for managing rodent population which act both as zoonotic vectors and cause agricultural losses.